Hugel Inc., a leading global medical aesthetics company, successfully hosted a launch event for its botulinum toxin product Botulax in the United Arab Emirates on May 9 at Desert Rose Yacht, Dubai.
This event, following the product’s debut in Kuwait, marked the second official launch in the Middle East and a significant milestone for Hugel's new chapter in the region with the slogan “Your Next Move.” The event, attended by about 180 local dermatologists and plastic surgeons, received great acclaim for its unique venue and high quality.
The event began with welcoming speeches from Andre Daoud, CEO of Medica Group, and Seanguk Ji, Vice President of Hugel. "It is a great honor to bring our competitive product Botulax to the UAE, the heart of the Middle Eastern beauty industry,” Ji said.
After the opening remarks, Dr. Erik Koppert, a key opinion leader in the Australian medical aesthetics industry and the main speaker of the event, shared insights on the efficacy and safety of Botulax based on clinical cases. He highlighted that Botulax won approval from the FDA last year with the product’s prowess and technological expertise.
Hugel aims to rapidly expand its presence across the Middle East by offering high-quality products at competitive prices, leveraging its Middle Eastern partner Medica Group’s wide distribution network and local market expertise.
“The launch event marks a start for our full-scale entry into the Middle East, and we saw strong interest from the attendees through the live Q&A session. We will quickly solidify our position with our differentiated product quality and customized local marketing strategies in the Middle East, which sees steady growth of demand for medical aesthetics,” a Hugel official said.
<br>
About Hugel
Established in 2001, Hugel is a global leader in medical aesthetics, specializing in the production of injectables for skin rejuvenation, including botulinum toxin, hyaluronic acid fillers, and skin boosters, as well as absorbable sutures and cosmetic products. As the market leader in injectable aesthetics in South Korea, Hugel is the only South Korean company with regulatory approvals in the world's three largest botulinum toxin markets: the US, China, and Europe. With a proven track record of safety and quality, Hugel is deeply committed to advancing the industry through robust medical affairs, comprehensive training programs, and dynamic industry forums. Over the past 20 years, the company has built a presence in approximately 70 countries and operates eight global subsidiaries across South Korea, the US, Australia, Canada, Taiwan, China, Hong Kong, and Singapore. Leveraging strong industry momentum, Hugel is poised for continued growth and global market expansion.
